The uptake and utility of genetic testing and genetic counseling for hypertrophic cardiomyopathy-A systematic review and meta-analysis

被引:10
|
作者
Cirino, Allison L. [1 ,2 ]
Harris, Stephanie L. [3 ]
Murad, Andrea M. [4 ]
Hansen, Brittany [5 ]
Malinowski, Jennifer [6 ]
Natoli, Jaime L. [7 ]
Kelly, Melissa A. [8 ]
Christian, Susan [9 ]
机构
[1] Brigham & Womens Hosp, Cardiovasc Div, 75 Francis St, Boston, MA 02115 USA
[2] MGH Inst Hlth Profess, 36 First Ave, Boston, MA 02129 USA
[3] Massachusetts Gen Hosp, Div Cardiol, Cardiovasc Genet Program, Boston, MA USA
[4] Univ Michigan, Div Med Genet, Dept Internal Med, Ann Arbor, MI USA
[5] Cleveland Clin, Genom Med Inst, Ctr Personalized Genet Healthcare, Cleveland, OH USA
[6] Write Inscite South Salem, New York, NY USA
[7] Kaiser Permanente, Southern Calif Permanente Med Grp, Pasadena, CA USA
[8] Genom Med Inst, Geisinger, Danville, PA USA
[9] Univ Alberta, Dept Med Genet, Edmonton, AB, Canada
关键词
cascade testing; genetic counseling; genetic testing; hypertrophic cardiomyopathy; predictive genetic testing; systematic review; utility; QUALITY-OF-LIFE; FOLLOW-UP; MUTATION CARRIERS; RELATIVES; CHILDREN; RISK; IMPACT; POPULATION; PENETRANCE; KNOWLEDGE;
D O I
10.1002/jgc4.1604
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Genetic testing and genetic counseling are routinely indicated for patients with hypertrophic cardiomyopathy (HCM); however, the uptake and utility of these services is not entirely understood. This systematic review and meta-analysis summarizes the uptake and utility of genetic counseling and genetic testing for patients with HCM and their at-risk family members, as well as the impact of genetic counseling/testing on patient-reported outcomes (PROs). A systematic search was performed through March 12, 2021. Meta-analyses were performed whenever possible; other findings were qualitatively summarized. Forty-eight studies met inclusion criteria (47 observational, 1 randomized). Uptake of genetic testing in probands was 57% (95% confidence interval [CI]: 40, 73). Uptake of cascade screening for at-risk relatives were as follows: 61% for cascade genetic testing (95% CI: 45, 75), 58% for cardiac screening (e.g. echocardiography) (95% CI: 40, 73), and 69% for either/both approaches (95% CI: 43, 87). In addition, relatives of probands with a positive genetic test result were significantly more likely to undergo cascade screening compared to relatives of probands with a negative result (odds ratio = 3.17, 95% CI: 2.12, 4.76). Overall, uptake of genetic counseling in both probands and relatives ranged from 37% to 84%. Multiple studies found little difference in PROs between individuals receiving positive versus negative genetic test results; however, other studies found that individuals with positive genetic test results experienced worse psychological outcomes. Genetic testing may also inform life choices, particularly decisions related to reproduction and insurance. Genetic counseling was associated with high satisfaction, increased perceived personal control and empowerment, and decreased anxiety. Approximately half to three-quarters of patients with HCM and their relatives undergo genetic testing or cascade screening. PROs after genetic testing varied and genetic counseling was associated with high satisfaction and improved PROs.
引用
收藏
页码:1290 / 1305
页数:16
相关论文
共 50 条
  • [21] Uptake of genetic counselling and predictive DNA testing in hypertrophic cardiomyopathy
    Imke Christiaans
    Erwin Birnie
    Gouke J Bonsel
    Arthur A M Wilde
    Irene M van Langen
    European Journal of Human Genetics, 2008, 16 : 1201 - 1207
  • [22] GENETIC TESTING FOR HYPERTROPHIC CARDIOMYOPATHY
    CLARKE, A
    HARPER, P
    NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (16): : 1175 - 1175
  • [23] Genetic Testing in Hypertrophic Cardiomyopathy
    Ireland, Catherine G.
    Ho, Carolyn Y.
    AMERICAN JOURNAL OF CARDIOLOGY, 2024, 212 : S4 - S13
  • [24] A systematic review and meta-analysis of telephone vs in-person genetic counseling in BRCA1/BRCA2 genetic testing
    Bracke, Xavier
    Roberts, Jonathan
    McVeigh, Terri P.
    JOURNAL OF GENETIC COUNSELING, 2021, 30 (02) : 563 - 573
  • [25] Current therapies for hypertrophic cardiomyopathy: a systematic review and meta-analysis of the literature
    Bayonas-Ruiz, Adrian
    Munoz-Franco, Francisca Maria
    Sabater-Molina, Maria
    Oliva-Sandoval, Maria Jose
    Gimeno, Juan R.
    Bonacasa, Barbara
    ESC HEART FAILURE, 2023, 10 (01): : 8 - 23
  • [26] Is There a Sex Difference in the Prognosis of Hypertrophic Cardiomyopathy? A Systematic Review and Meta-Analysis
    Zhao, Huilei
    Tan, Ziqi
    Liu, Menglu
    Yu, Peng
    Ma, Jianyong
    Li, Xiaozhong
    Wang, Jingfeng
    Zhao, Yujie
    Zhu, Wengen
    Liu, Xiao
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2023, 12 (11):
  • [27] EFFICACY OF MAVACAMTEN IN HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Naveed, Hamza
    Aimen, Shafi Q.
    Javeed, Zainab
    Naeem, Minahil
    Ali, Shafaqat
    Basit, Jawad
    Alam, Mahboob
    Hamza, Mohammad
    Almas, Talal
    Sattar, Yasar
    Alraies, M. Chadi
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 548 - 548
  • [28] GENETIC INVESTIGATION AND COUNSELING OF FAMILIES WITH HYPERTROPHIC CARDIOMYOPATHY
    DAVIES, MJ
    KRIKLER, DM
    BRITISH HEART JOURNAL, 1994, 72 (02): : 99 - 101
  • [29] Preimplantation genetic testing and disorders of placental implantation: a systematic review and meta-analysis
    Chamani, Isaac J.
    Taylor, Lauren L.
    Ciomperlik, Hailie
    Dunn, Timothy
    Reynolds, Anna C.
    Varman, Beatriz
    Fox, Karin A.
    Detti, Laura
    JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, 2025,
  • [30] Cascade genetic testing for hereditary cancer syndromes: A systematic review and meta-analysis
    Li, X.
    Kahn, R. M.
    Lackner, A. I.
    Nelson, B. Baltich
    Krinsky, H.
    Mei, E.
    Badiner, N.
    Holcomb, K. M.
    Chapman-Davis, E.
    Nitecki, R.
    Rauh-Hain, J. A.
    Sharaf, R.
    Frey, M. K.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 251 - 252